[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Japan Cancer Drug Pipeline Analysis

January 2014 | 557 pages | ID: J24D0192D19EN
PNS Pharma

US$ 1,500.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the options for its treatment have been major drivers for a rise in the research activities in this country.

With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has been the major source of funding for cancer research in all these years. However, of late, many non-governing organizations have also started to support basic and clinical research. This increased trend of forming strategic partnerships would be a major driver of the industry. Additionally, Japan has taken many steps to improve the drug lag system. With the increasing inclusion of Japanese in the global Phase III trials, the drug lag situation is set to improve for many cancers like gastric, non-small cell lung, breast, colorectal, hepatocellular carcinoma, and chronic myelogenous leukemia.

Additionally, licensing agreements are increasingly being used in this market and these have proved to be more efficient from both a strategic and financial point of view in the cancer market in Japan. There would a high upfront values and low development milestones in the form of high probability of approvals in the licensing deals made at a late stage. This is extremely beneficial from a strategic point of view, for the pharma companies in their every-day decision making.

“Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of various cancers. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Japan Cancer Drug Pipeline Analysis” research report:
  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class • ATC Codes
Number of Cancer Drugs in Pipeline by Clinical Phase:
  • Research: 23
  • Preclinical: 67
  • Clinical: 3
  • Phase-I: 98
  • Phase-I/II: 15
  • Phase-II: 26
  • Phase-II/III: 3
  • Phase-III: 37
  • Preregistration: 8
  • Registered: 8
  • Marketed: 90
  • Unknown: 1
1. JAPAN CANCER DRUG MARKET OVERVIEW

2. CANCER DRUG CLINICAL DEVELOPMENT PHASE: UNKNOWN

2.1 Overview
2.2 Cancer Drug Profile in Clinical Development Phase

3. CANCER DRUG CLINICAL DEVELOPMENT PHASE: RESEARCH

3.1 Overview
3.2 Cancer Drug Profile in Clinical Development Phase

4. CANCER DRUG CLINICAL DEVELOPMENT PHASE: PRECLINICAL

4.1 Overview
4.2 Cancer Drug Profile in Clinical Development Phase

5. CANCER DRUG CLINICAL DEVELOPMENT PHASE: CLINICAL

5.1 Overview
5.2 Cancer Drug Profile in Clinical Development Phase

6. CANCER DRUG CLINICAL DEVELOPMENT PHASE: PHASE-I

6.1 Overview
6.2 Cancer Drug Profile in Clinical Development Phase

7. CANCER DRUG CLINICAL DEVELOPMENT PHASE: PHASE-I/II

7.1 Overview
7.2 Cancer Drug Profile in Clinical Development Phase

8. CANCER DRUG CLINICAL DEVELOPMENT PHASE: PHASE-II

8.1 Overview
8.2 Cancer Drug Profile in Clinical Development Phase

9. CANCER DRUG CLINICAL DEVELOPMENT PHASE: PHASE-II/III

9.1 Overview
9.2 Cancer Drug Profile in Clinical Development Phase

10. CANCER DRUG CLINICAL DEVELOPMENT PHASE: PHASE-III

10.1 Overview
10.2 Cancer Drug Profile in Clinical Development Phase

11. CANCER DRUG CLINICAL DEVELOPMENT PHASE: PREREGISTRATION

11.1 Overview
11.2 Cancer Drug Profile in Clinical Development Phase

12. CANCER DRUG CLINICAL DEVELOPMENT PHASE: REGISTERED

12.1 Overview
12.2 Cancer Drug Profile in Clinical Development Phase

13. MARKETED

13.1 Overview
13.2 Marketed Cancer Drug Profile

EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC code
  • Designated Brand Name & Orphan Designation

Japan is a significant market for cancer and its related drugs in the Asia-Pacific region. Improved access to healthcare and an increased level of awareness about cancer and the  options  for  its  treatment  have  been  major  drivers  for  a  rise  in  the  research activities in this country. 

With the ageing population rapidly rising in Japan, cancer has become of the leading cause  of  concern.  Since  1982,  Japan  has  recorded  a  mortality  rate  of  one  in  three persons  dying  due  to  cancer.  The  Japanese  government  has  been  an  important contributor in taking efforts towards controlling the spread of this disease. There has been  significant  work  done  by  the  Ministry  of  Health  and  Welfare,  the  Ministry  of Education, Science, Culture and Sports and the Science and Science Technology Agency in this space. 

 The  Japanese  market  for  cancer-related  drugs  including  anticancer  agents,  colony-stimulating  factors,  antiemetics  and  pain  relievers  was  valued  approximately  at  xx billion yen in 2012. An increasing number of patients and incidence rates are the major factors driving this market. This market is expected to record a CAGR of 6-9% to reach an estimated value of xx billion yen by 2017. 

Of  the  total  cancer  drug  market,  the  anticancerdrug  segment  accounts  for  close  to 85%.  Another  segment  in  the  market  namely  the  oncology  agents  market,  which includes  hormone  therapies,  molecule  targeted  drugs,  antimetabolites,  microtubule inhibitors, platinum preparations, anticancer antibiotics and immuno-potentiators has been growing at a CAGR of 7-9% in recent years. 

The major reasons for the positive growth of Japanese cancer market is attributed to the  success  of  Avastin  (bevacizumab)  and  Tarceva  (erlotinib)  launched  by  Chugai, coupled  with  the  launches  of  Nexavar  (sorafenib),  Sutent  (sunitinib)  and  Elplat (oxaliplatin) by Bayer, Pfizer and Yakult respectively. The total sales of these agentsare  expected  to  cross  xx  billion  yen  by  2017  by  growing  at  a  very  rapid  rate.  The development of new drugs and the new targeted therapies has been a major driver of growth in this market.   

Owing to the increased level of awareness of the significance of palliative care among Japanese physicians and patients has led to a high growth in the revenues of cancer painkillers, which include opioids and non-opioids. It is most likely that this segment would  record  a  growth  rate  of  close  to  xx%  in  the  years  to  come  to  reach approximately xx billion yen by 2017. 

With the successful launch of the targeted therapeutics segment and identifying the extensive benefits of these new therapies, there has been the rise of novel strategies for  treatment  which  include  more  effective  combinations  of  chemotherapy  and hormonal  drugs.  These  are  likely  to  drive  the  demand  for  drugs  in  the  cancer treatment  market  in  Japan.  On  these  lines,  it  is  most  likely  that  the  segment  of targeted  therapies  alone  could  possibly  experience  the  maximum  significant  growth over the years to come which would inturn reflect on the increasing importance of this segment to the overall market. 

With the strong continued support from the government, the Japanese cancer market is expected to grow rapidly in the future years. The government has been the major source of funding for cancer research in all these years. However, of late, many non-governing organizations have also started to support basic and clinical research. This increased  trend  of  forming  strategic  partnerships  would  be  a  major  driver  of  the industry.  Additionally,  Japan  has  taken  many  steps  to  improve  the  drug  lag  system.

With  the  increasing  inclusion  of  Japanese  in  the  global  Phase  III  trials,  the  drug  lag situation is set to improve for many cancers like gastric, non-small cell lung, breast, colorectal, hepatocellular carcinoma, and chronic myelogenous leukemia. Additionally, licensing agreements are increasingly being used in this market and these have proved to be more efficient from both a strategic and financial point of view in the cancer market in Japan. There would a high upfront values and low development milestones in the form of high probability of approvals in the licensing deals made at a late stage. This is extremely beneficial from a strategic point of view, for the pharma companies in their every-day decision making. 

Thus, all these efforts are likely to provide the required push to the cancer market in Japan which is set to be placed on a growth trajectory.



More Publications